OpenLobby.EU
Explore

Bene Meat Technologies

BMT

Bene Meat Technologies is a biotechnology company providing a complete technological solution for cultivated meat production.

Lobbying Activity

Meeting with Peter Wehrheim (Head of Unit Research and Innovation)

23 Sept 2025 · Presentation of the biotech company “BeneMeat” focused on the research and development of technology to produce cultivated meat on the industrial scale

Response to European Research Area (ERA) Act

9 Aug 2025

SUBMISSION TO ERA ACT CONSULTATION From: Bene Meat Technologies a.s. Subject: Cellular Agriculture Innovation - Regulatory Harmonization Needs EXECUTIVE SUMMARY: As Europe's first cellular agriculture company with EU regulatory approval, we provide concrete evidence of innovation challenges and solutions within the European Research Area. 1. REGULATORY FRAGMENTATION IMPACT: Our experience demonstrates significant implementation variations across EU member states despite unified EU approval: CHALLENGE: EU Feed Materials Register approval (No. 009569-EN) requires different interpretations and additional requirements in different countries, creating operational barriers for innovative companies. IMPACT: Innovation scaling delayed, resources diverted from R&D to regulatory compliance navigation, and competitive disadvantage versus non-EU markets. SOLUTION NEEDED: Harmonized implementation guidelines for EU-approved innovative technologies across all member states. 2. CROSS-BORDER COLLABORATION BARRIERS: The current framework creates artificial boundaries for innovative technology companies operating across Europe. CHALLENGE: Different national interpretations of EU regulations prevent seamless European innovation deployment. SOLUTION NEEDED: Standardized implementation protocols ensuring EU approval recognition across all member states without additional barriers. 3. RESEARCH COMMERCIALIZATION GAPS: The gap between research excellence and commercial implementation affects European innovation competitiveness. CHALLENGE: Strong research capabilities but fragmented commercialization pathways reduce Europe's innovation leadership. SOLUTION NEEDED: Integrated research-to-market frameworks supporting breakthrough technologies from laboratory to commercial scale. 4. INNOVATION INVESTMENT COORDINATION: Current investment approaches don't adequately support breakthrough technologies requiring regulatory pioneering. CHALLENGE: Traditional investment metrics don't capture regulatory precedent value for innovative technologies. SOLUTION NEEDED: Investment frameworks recognizing regulatory approval as innovation infrastructure for European competitiveness. SPECIFIC ERA ACT RECOMMENDATIONS: A) REGULATORY HARMONIZATION MANDATE: - Require uniform implementation of EU-approved innovations across member states - Create enforcement mechanisms for consistent application - Establish appeal processes for regulatory interpretation disputes B) INNOVATION INFRASTRUCTURE DEVELOPMENT: - Recognize regulatory approval as a European innovation asset - Create pathways for regulatory precedent sharing across sectors - Support first-mover advantage development for European companies C) CROSS-BORDER INNOVATION FACILITATION: - Streamline European innovation company operations across borders - Remove artificial barriers to EU-approved technology deployment - Create innovative company mobility frameworks D) RESEARCH COMMERCIALIZATION ACCELERATION: - Bridge the gap between research excellence and commercial application - Support technology transfer from research institutions to commercial deployment - Create innovation-friendly regulatory environments CONCLUSION: The ERA Act presents a crucial opportunity to transform European innovation from fragmented national approaches to a unified European innovation leadership. Our experience in cellular agriculture demonstrates both current challenges and potential solutions for enhancing European innovation competitiveness.
Read full response

Meeting with Elena Arveras (Cabinet of Commissioner Maria Luís Albuquerque), Larisa Dragomir (Cabinet of Commissioner Maria Luís Albuquerque)

14 Jul 2025 · SIU and Sustainable Finance

Meeting with Klaus Berend (Director Health and Food Safety)

25 Jun 2025 · Exchange with the Commission on the company’s proposals to speed up the authorisation process for cell-culture based meat.